Several clinical trials indicated that this combination treatment has acceptable safety profiles and anti-tumour activity against ASS1-deficient solid tumors (Hall et al., 2019; Szlosarek et al., 2021; Yao et al., 2021; Chan et al., 2022). The gene discussed is ASS1; the disease is neoplasm.